Description: Learn about EPCLUSA® (sofosbuvir/velpatasvir) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1-6. See BOXED WARNING.
This information is intended for US healthcare professionals.
EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis.
Please see below for Important Safety Information for EPCLUSA.